Literature DB >> 3021337

Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

E Shtivelman, B Lifshitz, R P Gale, B A Roe, E Canaani.   

Abstract

The primary structure of normal abl protein was determined by sequencing the coding region of its cDNA. abl contains two alternative 5' exons spliced to a common set of 3' exons to yield the two major abl RNA transcripts. These transcripts initiate in different promoter regions and give rise to proteins that vary in their N-termini. In the human cell line K562, abl is translocated from chromosome 9 to within the bcr gene on chromosome 22. Within the fused bcr-abl gene, abl exon II alternatively splices to two adjacent bcr exons. This phenomenon is seen in many patients with chronic myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021337     DOI: 10.1016/0092-8674(86)90450-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  110 in total

1.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

2.  c-Abl antagonizes the YAP oncogenic function.

Authors:  R Keshet; J Adler; I Ricardo Lax; M Shanzer; Z Porat; N Reuven; Y Shaul
Journal:  Cell Death Differ       Date:  2014-10-31       Impact factor: 15.828

3.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

Review 4.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

6.  Characterization of a member of the immunoglobulin gene superfamily that possibly represents an additional class of growth factor receptor.

Authors:  Y H Chou; M J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

7.  DNA binding site of the growth factor-inducible protein Zif268.

Authors:  B Christy; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 9.  Current developments in molecular monitoring in chronic myeloid leukemia.

Authors:  Justine Ellen Marum; Susan Branford
Journal:  Ther Adv Hematol       Date:  2016-07-15

10.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.